Ann Arbor, MI – According to filings with the U.S. Securities and Exchange Commission, Enumera Molecular is raising $18,970,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Matthew Cooper played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Enumera Molecular
Enumera Molecular is a life science tools company developing rapid, low cost solutions for the of assessment of biomolecules via liquid biopsy. Enumera Molecular is a developer of a biomolecule assessment platform designed to offer life science tools. The company’s scalable platform transforms the field of clinical molecular testing into a simpler, more actionable tool, helping physicians to lower cost and rapid clinical liquid biopsy tests.

To learn more about Enumera Molecular, visit http://www.enumeramolecular.com

Contact:
Matthew Cooper, Chief Executive Officer
650-308-8544
matthew.cooper@enumeramolecular.com
https://www.linkedin.com/in/matthewtcooper/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved